WO2010014751A3 - Monoclonal antibody zt/2f2 in targeted therapy of cancers overexpressing the ron receptor tyrosine kinase - Google Patents

Monoclonal antibody zt/2f2 in targeted therapy of cancers overexpressing the ron receptor tyrosine kinase Download PDF

Info

Publication number
WO2010014751A3
WO2010014751A3 PCT/US2009/052155 US2009052155W WO2010014751A3 WO 2010014751 A3 WO2010014751 A3 WO 2010014751A3 US 2009052155 W US2009052155 W US 2009052155W WO 2010014751 A3 WO2010014751 A3 WO 2010014751A3
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibody
tyrosine kinase
receptor tyrosine
targeted therapy
ron receptor
Prior art date
Application number
PCT/US2009/052155
Other languages
French (fr)
Other versions
WO2010014751A2 (en
Inventor
Ming-hai WANG
Hang-Pping Yao
Original Assignee
Texas Tech University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas Tech University filed Critical Texas Tech University
Publication of WO2010014751A2 publication Critical patent/WO2010014751A2/en
Publication of WO2010014751A3 publication Critical patent/WO2010014751A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A method for treating a patient is provided. In accordance with the method, a suitable dosage of a pharmaceutical composition is applied to the patient, wherein the pharmaceutical composition comprises an antibody that binds to the RON receptor along a portion of its amino acid sequence identified by (SEQ ID NO: 1).
PCT/US2009/052155 2008-07-29 2009-07-29 Monoclonal antibody zt/2f2 in targeted therapy of cancers overexpressing the ron receptor tyrosine kinase WO2010014751A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13735508P 2008-07-29 2008-07-29
US61/137,355 2008-07-29

Publications (2)

Publication Number Publication Date
WO2010014751A2 WO2010014751A2 (en) 2010-02-04
WO2010014751A3 true WO2010014751A3 (en) 2010-05-06

Family

ID=41610948

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/052155 WO2010014751A2 (en) 2008-07-29 2009-07-29 Monoclonal antibody zt/2f2 in targeted therapy of cancers overexpressing the ron receptor tyrosine kinase

Country Status (1)

Country Link
WO (1) WO2010014751A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105916882A (en) * 2013-12-16 2016-08-31 得克萨斯技术大学联合体 Anti-RON monoclonal antibodies as a cytotoxic drug delivery system for targeted cancer therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040260064A1 (en) * 1996-12-16 2004-12-23 Amgen Inc. Antibodies to analogs of macrophage stimulating protein and uses thereof
WO2005120557A2 (en) * 2004-05-13 2005-12-22 Imclone Systems Incorporated Inhibition of macrophage-stimulating protein receptor (ron)
EP1892291A1 (en) * 2006-08-24 2008-02-27 Visgeneer, Inc. Human ron-related gene variant associated with cancers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040260064A1 (en) * 1996-12-16 2004-12-23 Amgen Inc. Antibodies to analogs of macrophage stimulating protein and uses thereof
WO2005120557A2 (en) * 2004-05-13 2005-12-22 Imclone Systems Incorporated Inhibition of macrophage-stimulating protein receptor (ron)
EP1892291A1 (en) * 2006-08-24 2008-02-27 Visgeneer, Inc. Human ron-related gene variant associated with cancers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CAMP ER ET AL.: "Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target.", CANCER., vol. 109, no. 6, 15 March 2007 (2007-03-15), pages 1030 - 1039 *
GERMANO, S. ET AL., MOLECULAR TARGETS IN CANCER THERAPY: THE RON APPROACH ONCOLOGY REVIEWS, vol. 1, no. 4, February 2008 (2008-02-01), pages 215 - 224 *
LU Y ET AL.: "Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets.", CANCER LETT., vol. 257, no. 2, 18 November 2007 (2007-11-18), pages 157 - 164 *

Also Published As

Publication number Publication date
WO2010014751A2 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
NZ597692A (en) Anti-IGF antibodies
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
AU2010305281C1 (en) Siglec 15 antibodies in treating bone loss-related disease
EP2532366A4 (en) Pharmaceutical composition for treating and/or preventing cancer
NZ604818A (en) Variants of activin iib receptor polypeptides and uses thereof
EP2532365A4 (en) Pharmaceutical composition for treatment and/or prevention of cancer
UA102061C2 (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
MX2009002711A (en) Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma.
UA99633C2 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
WO2012059598A3 (en) Methods of treating rheumatoid arthritis using il-17 antagonists
WO2008053330A3 (en) Monoclonal antibodies against the human anti-mullerian hormone type ii receptor (amhr-ii)
MX2010005966A (en) Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7).
NZ600512A (en) Neutralizing prolactin receptor antibodies and their therapeutic use
NZ607710A (en) 4-1bb binding molecules
RS53340B (en) High affinity human antibodies to human il-4 receptor
WO2010054265A3 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
MY187263A (en) Il-17 reception a antigen binding proteins
WO2006087637A3 (en) Anti her2/neu antibody
EP2431050A8 (en) Methods of treating cancer using IL-21 and monoclonal antibody therapy
TW200628490A (en) Novel anti-IGF-IR antibodies and uses thereof
NZ610267A (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2005087811A3 (en) Estrogen receptors and methods of use
WO2009025867A3 (en) Compositions of humanized notch fusion proteins and methods of treatment
MX2009007290A (en) Glucagon-like protein-1 receptor (glp-1r) agonist compounds.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09803564

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09803564

Country of ref document: EP

Kind code of ref document: A2